Our Team.
Jim Monsor
Jim has more than 35 years of experience in drug, device, and biologic development and commercialization. Executive leadership with startups and strategic partnerships. Background in operations, product development, quality and regulatory.
Jim Monsor
Chief Executive Officer
Robert Hoffman, M.D.
Robert has more than 40 years of experience as an Ophthamologist, internationally recognized clinician, teacher, inventor, scientist and author.
ROBERT HOFMANN, M.D.
Chief Scientific Officer
Marcus Henschen, R.N.
Marcus has more than ten years of experience in the healthcare field. His background is in biotetch and medical device startups as well as healthcare IT consulting and business development.
Marcus Henschen, RN
VP Business Development
Mitchell Brooks, M.D.
Mitchell has more than 35 years of experience as an orthopedic surgeon, healthcare strategy consultant, patient advocate, and healthcare entrepreneur.
Mitchell Brooks, M.D.
VP of Strategy
Advisory Board.
Mark Henschen, MBA, CFP
Mark has more than 35 years experience in financial services and financial management. Mark has served in numerous managerial capacities in the financial industry, most recently serving as CEO of a small cap bank where he remains chairman of the board of directors.
GEORGE DUNBAR
George has extensive healthcare and life sciences operating experience, and has served as an advisor, Director, or CEO with private and public companies in diagnostics, specialty pharma, cell therapy, and biologics. He is the managing partner of The Dunbar Group providing management services to the life sciences. The most recent assignment was CEO of Isto Biologics, Prior to ISTO Technologies, he served as a Venture Partner with Arboretum Ventures, and a director of four portfolio life science companies - two as executive chairman. He has held senior leadership positions with Ares-Serono (now Merck-Serono) and Amersham International (now GE Healthcare).
STAYKO STAYKOV
Stayko has over twenty years of experience in entrepreneurship, strategic asset management and advising in the areas of strategy development, mergers & acquisitions, intellectual property assets, technology licensing, and leadership development. He is also co-founder of Venture Grove and a director for Zyxogen.
Clint Hermes, JD
Clint is an attorney with extensive experience with the regulation of human and animal research, clinical trial registration and transparency, conflicts of interest, federal grants, biospecimens, data sharing, and expanded access to investigational products. His work on behalf of the research missions of academic medical centers and life sciences companies has taken him throughout Africa, Asia, the Middle East, and South America. He has served on numerous Institutional Review Boards (IRBs) in the United States and abroad, including as Vice Chair of a Harvard-affiliated IRB and of a biobank IRB abroad, and as science policy advisor to a foreign government.
Clint has authored numerous articles and book chapters (including one published by Oxford University Press) in the areas of international health projects and biomedical research and has been quoted in publications such as MIT’s Technology Review, Bloomberg Law, Modern Healthcare, and Canada’s Globe and Mail.